Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01215643 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants
A Phase 2 study, sponsored by Debiopharm International.
- Completed
- Registry status
- Phase 2
- Development phase
- 340
- Enrollment target
NCT01215643 is a Phase 2 study that has completed, run by Debiopharm International. The registered enrollment target is 340 participants.
The verdict
NCT01215643, a Phase 2 study, has completed, sponsored by Debiopharm International.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 340 participants
- Enrollment target
Study Summary
The study is to investigate whether alisporivir (ALV; DEB025) alone or in combination with either ribavirin (RBV) or peginterferon alfa-2a (PEG) is more efficient compared to standard of care (PEG+RBV) in treatment-naïve participants with hepatitis C virus (HCV) genotype 2 and 3. In addition, triple therapy with DEB025 plus standard of care will be applied to participants not achieving rapid viral response (RVR) in the different arms.
Interventions
- DRUG Ribavirin
- DRUG Peginterferon alfa-2a
- DRUG Alisporivir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 340 participants |
| Start Date | 2010-10 |
| Est. Completion | 2012-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01215643
The ClinicalTrials.gov registry entry for NCT01215643 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 340 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Debiopharm International, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ribavirin is the first listed.
NCT01215643 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01215643 about?
NCT01215643 is a clinical study titled "Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants". The study is to investigate whether alisporivir (ALV; DEB025) alone or in combination with either ribavirin (RBV) or peginterferon alfa-2a (PEG) is more efficient compared to standard of care (PEG+RBV) in treatment-naïve participants with hepatitis C virus (HCV) genotype 2 and 3. In addition, triple...
What is the current status of trial NCT01215643?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 340 participants. The study started on 2010-10. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01215643?
The interventions under investigation include: Ribavirin (DRUG), Peginterferon alfa-2a (DRUG), Alisporivir (DRUG).
Who is sponsoring clinical trial NCT01215643?
This trial is sponsored by Debiopharm International, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.